Zheng, Yan-qiu published the artcileCDC42 inhibitor ML141 suppresses laryngeal cancer Hep-2 cell proliferation, Related Products of pyrazoles-derivatives, the publication is Xiandai Shengwuyixue Jinzhan (2016), 16(4), 644-646, 651, database is CAplus.
Objective: Investigating the effect of CDC42 inhibitor ML141 on Hep-2 cell proliferation to provide new targets for mol. therapy of laryngeal cancer. Methods: Hep-2 cells were cultured in vitro. Real-time PCR was used to identify the expression of CDC42 in Hep-2 cell. GLISA was carried out to detect the changes in activation of CDC42 in Hep-2 cell treated with ML141. CCK8 assay was used to detect the effect of ML141 on Hep-2 cell proliferation. Results: 1. The result of Real-time PCR showed that CDC42 gene was differentially expressed in Hep-2 cells, which was consistent with the results of the whole genome profiling (P < 0.001). 2. The result of GLISA showed that epidermal growth factor (EGF) could increase the activation of CDC42 in Hep-2 cell but ML141 could inhibit its activation significantly (p < 0.001). 3. The result of CCK8 showed that the proliferation of Hep-2 cell was significantly inhibited by treating with ML141 after 24 h, 48 h and 72 h compared with control group (P < 0.001). Conclusion: CDC42 inhibitor ML141 could inhibit the proliferation of Hep-2 cell. ML141 might have the potential to become the new anti-cancer drug, which provided a new target point for mol. therapy of laryngeal cancer.
Xiandai Shengwuyixue Jinzhan published new progress about 71203-35-5. 71203-35-5 belongs to pyrazoles-derivatives, auxiliary class GPCR/G Protein,Ras, name is 4-(5-(4-Methoxyphenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide, and the molecular formula is C16H24BF4Ir, Related Products of pyrazoles-derivatives.
Referemce:
https://en.wikipedia.org/wiki/Pyrazole,
Pyrazoles – an overview | ScienceDirect Topics